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Recent findings have suggested that tau pathologymay spread in the brain by a prion-like mechanism. In this
issue of Neuron, de Calignon et al. (2012) recreated an early stage of neurofibrillary tangle pathology to show
that tau aggregates initially generated in a circumscribed area spread throughout the brain and lead to neuro-
degeneration.Neurofibrillary tangles (NFTs) composed
of a misfolded and aggregated form of
tau are a hallmark event in the patho-
genesis of Alzheimer’s disease (AD)
and other neurodegenerative disorders,
often called tauopathies, which include
fronto-temporal dementia, Pick’s dis-
ease, and chronic traumatic encephalop-
athy, among others. In spite of compelling
evidence indicating that NFTsplay amajor
role in neurodegeneration, little is known
about the mechanism and factors impli-
cated in the initiation and spreading of
this pathology in the brain.
Misfolding and aggregation is not
a unique feature of tau; indeed, misfolded
protein aggregates are implicated in
more than 20 human diseases, collec-
tively called protein misfolding disorders
(PMDs). The PMD group comprises highly
prevalent and insidious illnesses including
AD, Parkinson’s disease, and type 2 dia-
betes, as well as rarer disorders, such as
Huntington’s disease, systemic amyloid-
osis, amyotrophic lateral sclerosis, and
transmissible spongiform encephalopa-
thies (TSEs) (Chiti and Dobson, 2006;
Moreno-Gonzalez and Soto, 2011). Al-
though the proteins implicated in each of
these pathologies and the clinical mani-
festations of the diseases differ, the
molecular mechanism of protein misfold-
ing and the structural intermediates and
endpoint of the protein aggregation are
remarkably similar. Among PMDs, TSEs,
also known as prion diseases, are the
ones in which the causative role for the
accumulation of misfolded protein aggre-
gates are best established. This is
because TSEs can be acquired by infec-
tion, and compelling evidence indicates
that the misfolded prion protein is the
main (if not the sole) component of theinfectious agent (Soto, 2011). TSEs are
transmitted by the autocatalytic conver-
sion of the natively folded prion protein
seeded by the misfolded version of the
protein. In this manner, misfolded prion
aggregates spread throughout the body
and can occasionally, through defined
routes, transmit between individuals to
propagate the disease. Until recently,
the spreading and transmission of dis-
ease by propagation of protein misfolding
was thought to be an oddity of the rogue
prion protein. However, a series of recent
and exciting studies has shown experi-
mental evidence for prion-like mecha-
nisms of pathological spreading of mis-
folded proteins associated to various
diseases (Aguzzi and Rajendran, 2009;
Brundin et al., 2010; Moreno-Gonzalez
and Soto, 2011).
Various in vitro and in vivo studies have
reported that tau aggregates can spread
in the brain by a prion-like mechanism.
Experiments in cultured cells have shown
that extracellular tau aggregates can be
endocytosed by cells and can act as
seeds to induce themisfolding and aggre-
gation of intracellular tau (Frost et al.,
2009; Guo and Lee, 2011; Nonaka et al.,
2010). These intracellular tau aggregates
can further spread among cells to extend
the pathology to the entire culture. Intra-
cerebral injection of brain extract contain-
ing tau aggregates into transgenic mice
expressing human wild-type tau induced
the conversion of the native protein into
NFT-like aggregates in recipient mice
(Clavaguera et al., 2009). Interestingly,
the pathology spread over time beyond
the site of injection to synaptically con-
nected neighboring brain regions (Clava-
guera et al., 2009). These findings may
provide a mechanistic explanation forNeuron 73,the long-known, but puzzling, observation
that formation and accumulation of NFTs
in AD progresses with time in a stepwise
characteristic pattern. NFTs initiate in a
circumscribed area of the entorhinal cor-
tex, and pathology progresses in a topo-
graphically predictable manner across
limbic and association cortices through
anatomical connections (Braak and
Braak, 1991).
The elegant experiments reported in
this issue of Neuron by de Calignon et al.
(2012) provide further support for the
concept that NFTs spread in the brain
by a prion-like mechanism, probably ac-
counting for the stereotypical progres-
sion of NFT pathology in AD. A bigenic
mice model (termed rTgTauEC) in which
overexpression of human mutant
(P301L) tau is restricted to the layer II of
the entorhinal cortex (EC) was used for
these studies. In this way, the authors
recreated an early stage of AD NFT
pathology to investigate how tau aggre-
gates generated in a circumscribed area,
spread throughout the brain, and led
to neurodegeneration. The rTgTauEC
mouse model was generated by using a
previously described tetO-human P301L
tau mouse that only expresses the human
tau gene in the presence of a tet-transac-
tivator crossed with a mouse that
expresses the transactivator protein
under the control of the neuroserpin
promoter. A detailed analysis of the
human mutant tau gene expression by
various techniques showed that the
mRNA and the protein were detectable
mainly in the superficial layers of the
medial EC and the closely related pre-
and parasubicular cortices. Using this
model, the authors examined the appear-
ance and progression of tau pathology inFebruary 23, 2012 ª2012 Elsevier Inc. 621
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different ages. The results show that tau
pathology starts in neurons of the EC ex-
pressing the human transgene and over
time progresses to cells without detect-
able human tau expression, first in the
vicinity of the EC and later in more distant
regions located downstream in the syn-
aptic circuit, such as the dentate gyrus,
hippocampus, and cingulate cortex.
Human tau protein appears to spread to
these brain regions and to interact with
and induce aggregation of endogenous
mouse tau. The progressive accumulation
of tau aggregates leads to synaptic
degeneration and later to axonal damage
and neuronal death.
The exquisite regional specificity of the
human transgene expression combined
with the use of sophisticated techniques
to analyze the brain of these animals
enabled the authors to obtain a number
of important conclusions, namely: (1) tau
aggregates can transfer to neighboring
cells and to synaptically connected neu-
rons in distant parts of the brain, all of
which do not express detectable levels
of the human protein; (2) misfolded human
mutant tau recruits endogenous mouse
tau into the aggregates, leading to its
progressive intraneuronal accumulation;
(3) spreading of tau pathology induces
a slow synaptic destruction, followed by
axonal and later somatic degeneration of
neurons. These are important findings in
order to understand the progression of
tau pathology and associated damage in
AD, and they fit well with recent observa-
tions indicating that tau misfolding and
aggregation can spread from cell to cell
in a prion-like manner (Clavaguera et al.,
2009; Frost et al., 2009; Guo and Lee,
2011; Nonaka et al., 2010). However,
a potential weakness of the current study
is that, despite all the diverse techniques
used to evaluate human tau expression,
the authors cannot completely rule out
a low expression (below the level of
detection of the methods employed) of
the transgene in other brain areas.
Indeed, some leakiness of expression
has been reported previously for similar
mouse models (Santacruz et al., 2005).
In this scenario, low widespread expres-
sion of human P301L tau, and not
spreading of aggregates from one site to
another, may have seeded aggregation
of endogenous mouse tau and triggered622 Neuron 73, February 23, 2012 ª2012 Elsneurodegeneration. Although the authors
provide convincing evidence that expres-
sion beyond the targeted areas must be
very low (or nonexistent), it is also notice-
able that because of the high efficiency of
the seeding process, theseminute quanti-
ties may be enough to induce tau
aggregation.
A series of recent and exciting studies
has provided strong support for the
concept that the accumulation of mis-
folded protein aggregates, which is inti-
mately associated to the pathogenesis
of various neurodegenerative diseases,
is mediated by the intercellular spreading
of oligomeric seeds (Aguzzi and Rajen-
dran, 2009; Brundin et al., 2010). In
a manner similar to the infamous prions,
misfolded oligomers composed by
diverse proteins can act as a template to
induce the conversion of natively folded
proteins, propagating the abnormalities
to other cells, tissues, and organs. In the
case of tau pathology, the current study
by de Calignon et al., in addition to various
recent reports from other groups (Clava-
guera et al., 2009; Frost et al., 2009; Guo
and Lee, 2011; Nonaka et al., 2010), indi-
cates that misfolding and aggregation of
tau may start in a restricted area of the
brain and from there spread toward other
regions through synaptic connections,
leading to a progressive amplification of
the damage and expansion throughout
the brain. Many open questions regarding
this prion-like phenomenon of spreading
of tau misfolding still need to be ad-
dressed, including the following four
points.
(1) What are the factors and mecha-
nisms responsible for the formation of
the first misfolded tau seeds? In the
present study, pathology was initiated
by artificial expression of a human mutant
version of the tau gene in a defined brain
area. In the study by Clavaguera and
colleagues (2009), the seeds were intro-
duced by direct intracerebral injection of
brain homogenates containing tau aggre-
gates. It is possible to envision at least
three different ways in which the initial
seeds may arise. First, seeds may be
formed spontaneously in a particular
area of the brain, perhaps as a conse-
quence of somatic mutations, transcrip-
tional/translational errors, defects of the
proteostasis machinery, or tissue injury
(e.g., brain trauma or subclinical stroke),evier Inc.all of which are probably more frequent
during aging. Second, the initial seeds
may be acquired exogenously through
an ‘‘infection-like’’ process of exposure
to preformed aggregates. In prion dis-
eases, transmission between individuals
can occur through medical practices
(e.g., blood transfusion, organ trans-
plants, and use of materials or surgical
tools contaminated with prions), con-
sumption of food from animals carrying
misfolded prions, or vertical transmission
(Will, 2003). Third, misfolded aggregates
composed of one protein may interact
and promote the aggregation of another
protein by a phenomenon known as
cross-seeding. Evidence for this process
has been found for several PMDs, using
animal models, in vitro systems, and
human epidemiological analysis (see
Morales et al., 2009 and references
therein). It is also possible that non-
disease-associated aggregates (so-cal-
led functional amyloids) may also induce
misfolding of disease-related proteins
through cross-seeding (Johan et al.,
1998).
(2) What are the mechanisms respon-
sible for the transference of tau seeds
between cells? Studies with cellular
models of tau and a-synuclein suggest
that intracellular aggregates gain access
to the extracellular space either by secre-
tion or by damage of the host cell (Guo
and Lee, 2011; Nonaka et al., 2010).
Thereafter, extracellular aggregates can
get internalized to neighboring cells,
most likely through endocytosis, allowing
them to bind the natively folded protein
and seed the misfolding and aggregation
process (Frost et al., 2009; Guo and Lee,
2011; Nonaka et al., 2010). There have
also been reports indicating that cell-to-
cell spreading may occur through direct
cellular contact, involving nanotubes, or
mediated by exosomes or microvesicles
(Aguzzi and Rajendran, 2009).
(3) What are the structural features of
seed-competent misfolded proteins?
Misfolded proteins consist of a heteroge-
neous mixture of aggregates of variable
size. Elucidation of which of the different
species is responsible for propagating
the pathology is complicated by the lack
of sufficient knowledge regarding the
detailed structure of these aggregates
and the dynamic nature of the aggrega-
tion process. Considering purely
Neuron
Previewsphysicochemical characteristics, it seems
likely that freely circulating small oligo-
mers may be better seeds; however,
larger polymers may be more stable
against biological clearance.
(4) What are the molecular bases for the
selective cellular accumulation of NFTs?
Even though spreading of tau pathology
may provide a feasible explanation for
the mechanism by which deposition of
tau aggregates progresses in the brain
of AD patients, this phenomenon does
not explain why only some of the intercon-
nected neurons develop NFTs. The
reason behind the selective accumulation
of different types of misfolded aggregates
in distinct brain regions is a major
unknown in the field. Possible explana-
tions for this intriguing phenomenon could
be the involvement of cellular receptors,
the differential functioning of clearance
mechanisms, or the distinct level of
expression of the proteins involved in
misfolding.
The finding that tau pathology spreads
in the brain by a prion-like mechanism
not only helps us understand the processinvolved in disease pathogenesis and
provides a feasible explanation for the
stereotypical progression of these lesions
in AD brain but may also lead to the iden-
tification of new targets for therapeutic
intervention. Indeed, preventing the initial
formation of seeds or the subsequent
spreading of tau aggregates may repre-
sent interesting strategies for a much-
needed treatment for AD and related
tauopathies.REFERENCES
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In this issue of Neuron, Napoli et al. (2012) demonstrate that elevated ERK/MAPK signaling in Schwann cells
is a crucial trigger for Schwann cell dedifferentiation in vivo. Moreover, the authors show that dedifferentiated
Schwann cells have the potential to coordinate much of the peripheral nerve response to injury.A remarkable feature of the peripheral
nerve is the ability to regenerate after
injury. Regeneration is associated with
an extraordinary series of changes in
Schwann cells (reviewed in Chen et al.,
2007). After injury, Schwann cells dedif-
ferentiate into a progenitor-like state,
proliferate, and repopulate the damaged
nerve. In the nerve segment distal to the
site of injury, columns of dedifferentiatedSchwann cells form the Bands of Bungner
and provide an important substrate for
regenerating axons. Once axons have
regenerated, Schwann cells then redif-
ferentiate and remyelinate. Numerous
axonal-, Schwann cell-, and immune-
derived mediators are thought to be
required for the regenerative response.
Given the complex morphological
changes and the number of mediatorspotentially involved, it would seem un-
likely that the Schwann cell’s multifaceted
response to injury could be regulated by
a single pathway.
Indeed, within hours of nerve injury,
increased activity in multiple pathways
including ERK/MAPK, JNK/c-Jun, Notch,
and JAK-STAT can be detected in
Schwann cells (Sheu et al., 2000; Wood-
hoo et al., 2009). In vivo studies haveFebruary 23, 2012 ª2012 Elsevier Inc. 623
